Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Explore this paper's citation graph
Summary
In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared withperioperative ECF/ECX, and the number of toxic deaths was increased.
- Type
- article
- Published
- 2019-05-01
- Cited by
- 1,875
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2938774982
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:108292804
Keywords
Docetaxel, Medicine, Epirubicin, Capecitabine, Oxaliplatin
References
- Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
- Classification of adenocarcinoma of the oesophagogastric junction
- NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors
- Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
- S3-Leitlinie „Magenkarzinom” –
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
- Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
- Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
- Randomized clinical trial design for assessing noninferiority when superiority is expected.
- Preoperative chemoradiotherapy for esophageal or junctional cancer.
- Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice
- Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
- Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
- Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
- Benchmarking Complications Associated with Esophagectomy
Cited by
- Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting
- T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
- Two steps forward and one step back
- Perioperative FLOT: new standard for gastric cancer?
- Perioperative FLOT superior to ECF/X
- Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma
- More is not always better: triplet chemotherapy and advanced gastric cancer.
- Cardiorespiratory Comorbidity and Postoperative Complications following Esophagectomy: a European Multicenter Cohort Study
- MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database.
- Survival after neoadjuvant approaches to gastroesophageal junction cancer
- Recent eUpdates to the ESMO Clinical Practice Guidelines on Hepatocellular Carcinoma, Cancer of the Pancreas, Soft Tissue and Visceral Sarcomas, Cancer of the Prostate and Gastric Cancer.
- Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
- Gastric Cancer - From Aetiology to Management: Differences Between the East and the West.
- How I treat gastric adenocarcinoma
- Robotic-assisted gastrectomy for gastric cancer: a European perspective
- Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer.
- Diagnostik und Therapie des Ösophaguskarzinoms
- COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
- Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
- Multiple Synchronous Tumours: A Peculiar Clinical Case
Related papers
- Study of oxaliplatin combined with capecitabine for advanced gastric cancer
- Clinical Observation of Oxaliplatin Combined with Capecitabine for Advanced Gastric Cancer
- Analyzed the treatment effect of advanced gastric cancer about S-1 and Capecitabine combined with oxaliplatin
- The Clinical Observation of Oxaliplatin in Combination with Capecitabine in Patients with Advanced Gastric Cancer
- Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors: A Phase I Study
- 07 / COMPARISON OF OXALIPLATIN-RELATED SPLEEN ENLARGEMENT IN PATIENT WITH GASTRIC CANCER WHO RECEIVED S-1 VERSUS CAPECITABINE AS A COMBINATION PARTNER OF OXALIPLATIN
- Clinical observation of chemotherapy of Capecitabine combined with Oxaliplatin in treatment of advanced gastric cancer